Corectim — Competitive Intelligence Brief

Corectim (DELGOCITINIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Janus Kinase Inhibitor [EPC]. Area: Immunology.

marketed Janus Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK2 Immunology Small molecule

Target snapshot

Corectim (DELGOCITINIB) — Japan Tobacco. Delgocitinib works by blocking the JAK2 enzyme, which plays a key role in the immune system's inflammatory response.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Corectim TARGET	DELGOCITINIB	Japan Tobacco	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK2
Vonjo	PACRITINIB	Sobi	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK2	2022-01-01
Olumiant	baricitinib	Eli Lilly	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK2	2018-01-01
Cibinqo	abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
Cibinqo	Abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
ABROCITINIB	ABROCITINIB		marketed	Janus Kinase Inhibitor [EPC]	JAK1	2021-01-01
BARICITINIB	BARICITINIB		marketed	Janus Kinase Inhibitor [EPC]		2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Janus Kinase Inhibitor [EPC] class)

1. · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Eli Lilly · 1 drug in this class
4. Japan Tobacco · 1 drug in this class